Scott W. White
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Scott W. White has a total of 145 co-authors. Here are the top co-authors by number of shared publications:
- Carrington C. J. Shepherd
Curtin Medical School, Curtin University, Bentley, Australia
9 shared publications - John P. Newnham
Division of Obstetrics and Gynaecology University of Western Australia Subiaco WA Australia
8 shared publications - Akilew Awoke Adane
Murdoch University
7 shared publications - Brad Farrant
The Kids Research Institute Australia, Nedlands, WA, Australia
7 shared publications - Craig Edward Pennell
School of Medicine and Public Health, University of Newcastle, Newcastle, Australia
7 shared publications - Helen D. Bailey
Curtin Medical School, Faculty of Health Sciences Curtin University Perth Western Australia Australia
7 shared publications
Latest Publications
- 1 June 2025
- Published by Wiley in Australian and New Zealand Journal of Obstetrics and Gynaecology
- Vol. 65 (3) , 309-311
Editor‐In‐Chief's Introduction to ANZJOG 65(3)
- 1 June 2025
- Published by Wiley in Australian and New Zealand Journal of Obstetrics and Gynaecology
- Vol. 65 (3) , 309-311
Editor‐In‐Chief's Introduction to ANZJOG 65(3)
- Open Access
- 11 April 2025
- Published by Wiley in Australian and New Zealand Journal of Obstetrics and Gynaecology
- Vol. 65 (5) , 671-680
Verbal Information From Parents About Stillbirth: The VIPS Study (Phase One)
Background: In many countries, a baby's cause of death (COD) following stillbirth is informed only by case notes and pathology investigations. However, parents' understanding of their baby's COD may inform or even change the COD diagnosis. We aimed to produce a standardised co‐designed interview schedule to enable parents to contribute information to improve overall understanding of the causes of stillbirth. Materials and Methods: Consensus for the interview schedule was sought via a two‐round modified Delphi study. We recruited internationally for panel membership comprising bereaved parents, clinicians, and researchers. In Round 1, each panellist provided up to five questions to ask bereaved parents. After collation into categories, Round 2 asked panellists to rate the importance of each question category on a four‐point scale. Results: Panellists ( n = 126 Round 1, n = 75 Round 2) were mainly bereaved parents. In Round 1, 553 potential interview questions were generated. These were grouped into categories which were pregnancy experience, antenatal care, fetal wellbeing, maternal wellbeing, days Prior to stillbirth and perceived COD. These proposed questions and question categories were then put to panel members in Round 2. All categories achieved consensus for inclusion in the final interview schedule with positive consensus percentage scores ranging from 83% to 98%. Conclusions: Panel membership comprising mainly bereaved parents provided a clear mandate for questions parents want to be asked. The interview schedule will soon be trialled with recently bereaved parents at a tertiary‐referral maternity health service. Findings from the study will inform future research on how to include parents' voices in COD determination.
- 11 April 2025
- Published by Wiley in Australian and New Zealand Journal of Obstetrics and Gynaecology
- Vol. 65 (5) , 671-680
Open AccessVerbal Information From Parents About Stillbirth: The VIPS Study (Phase One)
Background: In many countries, a baby's cause of death (COD) following stillbirth is informed only by case notes and pathology investigations. However, parents' understanding of their baby's COD may inform or even change the COD diagnosis. We aimed to produce a standardised co‐designed interview schedule to enable parents to contribute information to improve overall understanding of the causes of stillbirth. Materials and Methods: Consensus for the interview schedule was sought via a two‐round modified Delphi study. We recruited internationally for panel membership comprising bereaved parents, clinicians, and researchers. In Round 1, each panellist provided up to five questions to ask bereaved parents. After collation into categories, Round 2 asked panellists to rate the importance of each question category on a four‐point scale. Results: Panellists ( n = 126 Round 1, n = 75 Round 2) were mainly bereaved parents. In Round 1, 553 potential interview questions were generated. These were grouped into categories which were pregnancy experience, antenatal care, fetal wellbeing, maternal wellbeing, days Prior to stillbirth and perceived COD. These proposed questions and question categories were then put to panel members in Round 2. All categories achieved consensus for inclusion in the final interview schedule with positive consensus percentage scores ranging from 83% to 98%. Conclusions: Panel membership comprising mainly bereaved parents provided a clear mandate for questions parents want to be asked. The interview schedule will soon be trialled with recently bereaved parents at a tertiary‐referral maternity health service. Findings from the study will inform future research on how to include parents' voices in COD determination.
- 1 April 2025
- Published by Wiley in Australian and New Zealand Journal of Obstetrics and Gynaecology
- Vol. 65 (2) , 181-182
Editor‐In‐Chief's Introduction to ANZJOG 65(2)
- 1 April 2025
- Published by Wiley in Australian and New Zealand Journal of Obstetrics and Gynaecology
- Vol. 65 (2) , 181-182
Editor‐In‐Chief's Introduction to ANZJOG 65(2)
- 1 February 2025
- Published by Wiley in Australian and New Zealand Journal of Obstetrics and Gynaecology
- Vol. 65 (1) , 3-5
ANZJOG in 2025
- 1 February 2025
- Published by Wiley in Australian and New Zealand Journal of Obstetrics and Gynaecology
- Vol. 65 (1) , 3-5
ANZJOG in 2025
- 30 December 2024
- Published by Wiley in Australian and New Zealand Journal of Obstetrics and Gynaecology
- Vol. 64 (6) , 537-539
Editor‐In‐Chief's Introduction to ANZJOG 64(6)
- 30 December 2024
- Published by Wiley in Australian and New Zealand Journal of Obstetrics and Gynaecology
- Vol. 64 (6) , 537-539
Editor‐In‐Chief's Introduction to ANZJOG 64(6)
- 1 October 2024
- Published by Wiley in Australian and New Zealand Journal of Obstetrics and Gynaecology
- Vol. 64 (5) , 421-422
Editor‐in‐Chief's introduction to ANZJOG 64 (5)
- 1 October 2024
- Published by Wiley in Australian and New Zealand Journal of Obstetrics and Gynaecology
- Vol. 64 (5) , 421-422
Editor‐in‐Chief's introduction to ANZJOG 64 (5)
- Open Access
A double-blind, randomised, placebo-controlled trial to evaluate the effectiveness of late gestation oral melatonin supplementation in reducing induction of labour rates in nulliparous women. The MyTIME study protocol
Introduction: Around the world, rates of induction of labour (IOL) amongst nulliparous mothers have increased in the last 10 years. In Australia, rates have increased over the last decade by 43%, from 32% to 46%. There is growing concern about the rapid rise in IOL before 41 weeks for nulliparous women without medical complications because of the associated increased rates of caesarean section, reduced satisfaction with birth, and birth trauma. Melatonin potentiates the action of oxytocin and may promote the spontaneous onset of labour; therefore, we will test the hypothesis that exogenous melatonin supplementation in late pregnancy will reduce the rate of labour induction by 30% or more. Methods and analyses: This is a double-blind, randomised, placebo-controlled trial in nulliparous pregnant women to reduce IOL rates. We will randomise 530 women to receive either 3 mg oral melatonin or placebo daily from 39 +0 weeks gestation until they give birth. The primary endpoint will be IOL rate after 39 weeks. Secondary endpoints will include: interval between administration of trial medication and birth; a range of maternal and neonatal outcomes, including birth outcomes; breastfeeding on discharge, at 10 days and at 2 months; maternal satisfaction; child developmental outcomes at 2 months of age; and cost-effectiveness of melatonin compared with standard care. All data will be analysed by intention to treat. Ethics and dissemination: The study is approved by the Women and Newborn Health Service (WNHS) Human Research Ethics Committee (HREC) (RGS0000006283). Trial findings will be disseminated through conference presentations and peer reviewed publications. Trial registration number: The trial has been prospectively registered on the Australian New Zealand Clinical Trials Registry as ACTRN12623000502639 Strengths and Limitations: placebo-controlled clinical trial: This is the first registered randomised placebo-controlled clinical trial investigating the effect of melatonin to improve the onset of spontaneous labour from 39 weeks gestation and therefore, reduce the rates of women requiring IOL. Both participants and clinicians will be blinded to intervention allocation, ensuring decisions regarding induction of labour cannot be influenced by the allocation. Exploration of child developmental outcomes is a strength, not previously undertaken in trials including melatonin supplementation in pregnancy. Sub study findings from participants with Gestational Diabetes Mellitus (GDM) will provide novel pilot data regarding the potential role for melatonin in blood glucose control. A limitation of our trial is that is conducted within one health service area which may limit generalisability; however, this area is large, encompassing 4 separate sites, various models of care and all capability levels of maternity care (primary through to quaternary) minimising the impact of this selection bias. Singular health service governance over such a large variety of settings supports protocol implementation and compliance, reducing variability and improving trial quality.
Open AccessA double-blind, randomised, placebo-controlled trial to evaluate the effectiveness of late gestation oral melatonin supplementation in reducing induction of labour rates in nulliparous women. The MyTIME study protocol
Introduction: Around the world, rates of induction of labour (IOL) amongst nulliparous mothers have increased in the last 10 years. In Australia, rates have increased over the last decade by 43%, from 32% to 46%. There is growing concern about the rapid rise in IOL before 41 weeks for nulliparous women without medical complications because of the associated increased rates of caesarean section, reduced satisfaction with birth, and birth trauma. Melatonin potentiates the action of oxytocin and may promote the spontaneous onset of labour; therefore, we will test the hypothesis that exogenous melatonin supplementation in late pregnancy will reduce the rate of labour induction by 30% or more. Methods and analyses: This is a double-blind, randomised, placebo-controlled trial in nulliparous pregnant women to reduce IOL rates. We will randomise 530 women to receive either 3 mg oral melatonin or placebo daily from 39 +0 weeks gestation until they give birth. The primary endpoint will be IOL rate after 39 weeks. Secondary endpoints will include: interval between administration of trial medication and birth; a range of maternal and neonatal outcomes, including birth outcomes; breastfeeding on discharge, at 10 days and at 2 months; maternal satisfaction; child developmental outcomes at 2 months of age; and cost-effectiveness of melatonin compared with standard care. All data will be analysed by intention to treat. Ethics and dissemination: The study is approved by the Women and Newborn Health Service (WNHS) Human Research Ethics Committee (HREC) (RGS0000006283). Trial findings will be disseminated through conference presentations and peer reviewed publications. Trial registration number: The trial has been prospectively registered on the Australian New Zealand Clinical Trials Registry as ACTRN12623000502639 Strengths and Limitations: placebo-controlled clinical trial: This is the first registered randomised placebo-controlled clinical trial investigating the effect of melatonin to improve the onset of spontaneous labour from 39 weeks gestation and therefore, reduce the rates of women requiring IOL. Both participants and clinicians will be blinded to intervention allocation, ensuring decisions regarding induction of labour cannot be influenced by the allocation. Exploration of child developmental outcomes is a strength, not previously undertaken in trials including melatonin supplementation in pregnancy. Sub study findings from participants with Gestational Diabetes Mellitus (GDM) will provide novel pilot data regarding the potential role for melatonin in blood glucose control. A limitation of our trial is that is conducted within one health service area which may limit generalisability; however, this area is large, encompassing 4 separate sites, various models of care and all capability levels of maternity care (primary through to quaternary) minimising the impact of this selection bias. Singular health service governance over such a large variety of settings supports protocol implementation and compliance, reducing variability and improving trial quality.
- 5 August 2024
- Published by Wiley in Australian and New Zealand Journal of Obstetrics and Gynaecology
- Vol. 64 (4) , 303-304
Editor‐in‐chief's introduction to ANZJOG 64 (4)
- 5 August 2024
- Published by Wiley in Australian and New Zealand Journal of Obstetrics and Gynaecology
- Vol. 64 (4) , 303-304
Editor‐in‐chief's introduction to ANZJOG 64 (4)
- 1 June 2024
- Published by Wiley in Australian and New Zealand Journal of Obstetrics and Gynaecology
- Vol. 64 (3) , 173-175
Editor‐in‐Chief's introduction to ANZJOG 64 (3)
- 1 June 2024
- Published by Wiley in Australian and New Zealand Journal of Obstetrics and Gynaecology
- Vol. 64 (3) , 173-175
Editor‐in‐Chief's introduction to ANZJOG 64 (3)
- 10 April 2024
- Published by Wiley in Australian and New Zealand Journal of Obstetrics and Gynaecology
- Vol. 64 (2) , 83-84
Editor‐in‐chief's introduction toANZJOG64(2)
- 10 April 2024
- Published by Wiley in Australian and New Zealand Journal of Obstetrics and Gynaecology
- Vol. 64 (2) , 83-84
Editor‐in‐chief's introduction toANZJOG64(2)